Microbot Medical Inc
microbotmedical.comWhat Do They Do?
Develops and sells a remotely operated robotic system for endovascular procedures to hospitals and other healthcare providers.
10-K for FY2025, filed Mar 26, 2026Microbot is a medical device company specializing in the research, design and development of next generation robotic endoluminal surgery…View ↗
Using our LIBERTY® technological platform, we have developed the first-ever fully disposable robot for various endovascular interventional…View ↗
CommercializationView ↗
In November 2025, we announced the limited market release of LIBERTY® to selected high procedure volume regions where we already…View ↗
Who Are Their Customers?
Hospitals and health systems use LIBERTY for patient care; the company has built U.S. sales and distribution capabilities and plans to use distributors and strategic partnerships outside the United States.
10-K for FY2025, filed Mar 26, 2026In 2025, Microbot established a sales, marketing and product distribution infrastructure for the LIBERTY® Endovascular Robotic System in…View ↗
In November 2025, we announced the limited market release of LIBERTY® to selected high procedure volume regions where we already…View ↗
Microbot has not yet developed a commercial strategy outside of the United States, but it most likely would utilize distributors and…View ↗
How Are They Changing?
-
Aug 11, 2026
LIBERTY full market release expanded sales and customer use
New health systems adopted the system, existing customers added hospital sites, and procedure volume increased.
Sources
8-K, filed Aug 11, 2026
Commenced the Full Market Release (FMR) of the LIBERTY System during The Society of Interventional Radiology (SIR) Annual Scientific…View ↗
-
Jul 7, 2026
LIBERTY revenue and new customers grew more than 100%
The company reported growth in the second quarter compared with the first quarter and expanded into new health systems.
Sources
8-K, filed Jul 7, 2026
Microbot Medical Inc. has reported a greater than 100% growth in revenue and new customers for the second quarter ended June 30, 2026…View ↗
Narrower product focus
The older report described a broader pipeline that included several technology platforms and multiple endovascular markets. The latest report centers on LIBERTY and describes peripheral procedures as its current focus, with other markets for future versions.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026
From development to commercialization
The older report presented LIBERTY as under development and preparing for regulatory steps. The latest report says the system received FDA clearance, entered limited market release, and has a U.S. sales, marketing, and distribution infrastructure.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026On September 8, 2025, we announced that the FDA has granted 510(k) clearance for the LIBERTY® Endovascular Robotic Surgical System, and in…View ↗
In 2025, Microbot established a sales, marketing and product distribution infrastructure for the LIBERTY® Endovascular Robotic System in…View ↗
In November 2025, we announced the limited market release of LIBERTY® to selected high procedure volume regions where we already…View ↗
Who Do They Compete With?
Competes with Corindus Vascular Robotics, Robocath, LN Robotics, Nanoflex Robotics, UAB Inovatyvi medicina, and Endoways
10-K for FY2025, filed Mar 26, 2026We believe the main competitor to the LIBERTY® Endovascular Robotic Surgical System is the CorPath GRX vascular robotics system by Corindus…View ↗
Loading...
